{"id":"https://openalex.org/W2532017670","doi":"https://doi.org/10.1021/acschemneuro.6b00337","title":"Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression","display_name":"Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression","publication_year":2016,"publication_date":"2016-10-17","ids":{"openalex":"https://openalex.org/W2532017670","doi":"https://doi.org/10.1021/acschemneuro.6b00337","mag":"2532017670","pmid":"https://pubmed.ncbi.nlm.nih.gov/27744678"},"language":"en","primary_location":{"id":"doi:10.1021/acschemneuro.6b00337","doi":"https://doi.org/10.1021/acschemneuro.6b00337","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acschemneuro.6b00337","pdf_url":null,"source":{"id":"https://openalex.org/S180465690","display_name":"ACS Chemical Neuroscience","issn_l":"1948-7193","issn":["1948-7193"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Chemical Neuroscience","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041084487","display_name":"Andrew P. Degnan","orcid":"https://orcid.org/0000-0001-6210-9501","observed_orcids":["https://orcid.org/0000-0001-6210-9501"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew P. Degnan","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012165450","display_name":"George O. Tora","orcid":"https://orcid.org/0000-0002-7232-5774","observed_orcids":["https://orcid.org/0000-0002-7232-5774"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George O. Tora","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hong Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Huang","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035757280","display_name":"David A. Conlon","orcid":"https://orcid.org/0000-0002-6062-4515","observed_orcids":["https://orcid.org/0000-0002-6062-4515"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Conlon","raw_affiliation_strings":["Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103462797","display_name":"Carl D. Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carl D. Davis","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037690185","display_name":"Umesh Hanumegowda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Umesh M. Hanumegowda","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082703411","display_name":"Xiaoping Hou","orcid":"https://orcid.org/0000-0001-6169-3443","observed_orcids":["https://orcid.org/0000-0001-6169-3443"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoping Hou","raw_affiliation_strings":["Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110037621","display_name":"Yi Hsiao","orcid":"https://orcid.org/0009-0000-2528-0844","observed_orcids":["https://orcid.org/0009-0000-2528-0844"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yi Hsiao","raw_affiliation_strings":["Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060087004","display_name":"Joanna K. Hu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanna Hu","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031044594","display_name":"Rudolph G. Krause","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rudolph Krause","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100619887","display_name":"Yu-Wen Li","orcid":"https://orcid.org/0000-0003-1627-8376","observed_orcids":["https://orcid.org/0000-0003-1627-8376"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Wen Li","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053427669","display_name":"Amy E. Newton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy E. Newton","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058102521","display_name":"Rick L. Pieschl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rick L. Pieschl","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035901345","display_name":"Joseph J. Raybon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Raybon","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079436433","display_name":"Thorsten Rosner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thorsten Rosner","raw_affiliation_strings":["Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical\rDevelopment, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111042377","display_name":"Jung\u2010Hui Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jung-Hui Sun","raw_affiliation_strings":["Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013435178","display_name":"Matthew T. Taber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew T. Taber","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sarah J. Taylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah J. Taylor","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael K. Wong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael K. Wong","raw_affiliation_strings":["Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Huiping Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Huiping Zhang","raw_affiliation_strings":["Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemical Synthesis, Bristol-Myers Squibb Company, Princeton, New Jersey 08543, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038254883","display_name":"Nicholas J. Lodge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas J. Lodge","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081649221","display_name":"Joanne J. Bronson","orcid":"https://orcid.org/0009-0003-9719-3493","observed_orcids":["https://orcid.org/0009-0003-9719-3493"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanne J. Bronson","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070894857","display_name":"John E. Macor","orcid":"https://orcid.org/0009-0000-9040-5770","observed_orcids":["https://orcid.org/0009-0000-9040-5770"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John E. Macor","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083827325","display_name":"Kevin W. Gillman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin W. Gillman","raw_affiliation_strings":["Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, United States","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5041084487"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.4191,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.64746408,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"7","issue":"12","first_page":"1635","last_page":"1640"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.7627000212669373,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.7627000212669373,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.09139999747276306,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.016499999910593033,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/indazole","display_name":"indazole","score":0.8889999985694885},{"id":"https://openalex.org/keywords/nk1-receptor-antagonists","display_name":"NK1 receptor antagonists","score":0.9800000190734863},{"id":"https://openalex.org/keywords/serotonin-transporter-inhibitors","display_name":"serotonin transporter inhibitors","score":0.9919999837875366},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.7559999823570251},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8510000109672546},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6230000257492065},{"id":"https://openalex.org/keywords/ion-channel-block","display_name":"ion channel blockade","score":0.8640000224113464},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.9200000166893005},{"id":"https://openalex.org/keywords/brain-uptake","display_name":"brain uptake","score":0.9729999899864197},{"id":"https://openalex.org/keywords/depression-model","display_name":"depression model","score":0.5899999737739563},{"id":"https://openalex.org/keywords/asymmetric-hydrogenation","display_name":"asymmetric hydrogenation","score":0.8450000286102295}],"concepts":[{"id":"https://openalex.org/C2778897192","wikidata":"https://www.wikidata.org/wiki/Q410142","display_name":"Serotonin transporter","level":4,"score":0.783742368221283},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6775579452514648},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.5153672099113464},{"id":"https://openalex.org/C53910766","wikidata":"https://www.wikidata.org/wiki/Q238516","display_name":"5-HT receptor","level":4,"score":0.44233301281929016},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.4351838529109955},{"id":"https://openalex.org/C2910584757","wikidata":"https://www.wikidata.org/wiki/Q334477","display_name":"Serotonin Uptake Inhibitors","level":5,"score":0.4300849437713623},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.41456088423728943},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39806410670280457},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3767615258693695},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.33768755197525024},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.19321709871292114},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12887439131736755},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11742070317268372},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.08651915192604065}],"mesh":[{"descriptor_ui":"D000071230","descriptor_name":"Transcriptional Regulator ERG","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005849","descriptor_name":"Gerbillinae","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D018040","descriptor_name":"Receptors, Neurokinin-1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D050486","descriptor_name":"Serotonin Plasma Membrane Transport Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064729","descriptor_name":"Neurokinin-1 Receptor Antagonists","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D064729","descriptor_name":"Neurokinin-1 Receptor Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D064729","descriptor_name":"Neurokinin-1 Receptor Antagonists","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D064729","descriptor_name":"Neurokinin-1 Receptor Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/acschemneuro.6b00337","doi":"https://doi.org/10.1021/acschemneuro.6b00337","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acschemneuro.6b00337","pdf_url":null,"source":{"id":"https://openalex.org/S180465690","display_name":"ACS Chemical Neuroscience","issn_l":"1948-7193","issn":["1948-7193"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Chemical Neuroscience","raw_type":"journal-article"},{"id":"pmid:27744678","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27744678","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS chemical neuroscience","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W578782044","https://openalex.org/W1508200337","https://openalex.org/W1972504730","https://openalex.org/W1979617003","https://openalex.org/W1992562625","https://openalex.org/W2008661553","https://openalex.org/W2016560535","https://openalex.org/W2018285323","https://openalex.org/W2020802357","https://openalex.org/W2024053543","https://openalex.org/W2025534441","https://openalex.org/W2028733293","https://openalex.org/W2028977103","https://openalex.org/W2030926855","https://openalex.org/W2033745488","https://openalex.org/W2052714177","https://openalex.org/W2053472601","https://openalex.org/W2056421884","https://openalex.org/W2062458432","https://openalex.org/W2062815987","https://openalex.org/W2064342700","https://openalex.org/W2065463514","https://openalex.org/W2073233024","https://openalex.org/W2089299823","https://openalex.org/W2106623141","https://openalex.org/W2107125549","https://openalex.org/W2111439580","https://openalex.org/W2118659222","https://openalex.org/W2140660757","https://openalex.org/W2143608139","https://openalex.org/W2149402043","https://openalex.org/W2159853732","https://openalex.org/W4414041363"],"related_works":["https://openalex.org/W2091411195","https://openalex.org/W2057928528","https://openalex.org/W578782044","https://openalex.org/W2040149023","https://openalex.org/W2953061773","https://openalex.org/W2048159769","https://openalex.org/W2141416468","https://openalex.org/W2173099906","https://openalex.org/W1964936971","https://openalex.org/W2117374080"],"abstract_inverted_index":{"Combination":[0],"studies":[1],"of":[2,19,32,41,49,61,71,97,110],"neurokinin":[3],"1":[4],"(NK1)":[5],"receptor":[6,53],"antagonists":[7],"and":[8,39,84],"serotonin-selective":[9],"reuptake":[10],"inhibitors":[11,57],"(SSRIs)":[12],"have":[13],"shown":[14],"promise":[15],"in":[16,68,86,89],"preclinical":[17],"models":[18],"depression.":[20],"Such":[21],"a":[22,47,90,100],"combination":[23],"may":[24],"offer":[25],"important":[26],"advantages":[27],"over":[28],"the":[29,37,69,95,111],"current":[30],"standard":[31],"care.":[33],"Herein":[34],"we":[35],"describe":[36],"discovery":[38],"optimization":[40],"an":[42,74],"indazole-based":[43],"chemotype":[44],"to":[45,58,107],"provide":[46],"series":[48],"potent":[50],"dual":[51],"NK1":[52],"antagonists/serotonin":[54],"transporter":[55],"(SERT)":[56],"overcome":[59],"issues":[60],"ion":[62],"channel":[63],"blockade.":[64],"This":[65],"effort":[66],"culminated":[67],"identification":[70],"compound":[72],"9,":[73],"analogue":[75],"that":[76],"demonstrated":[77],"favorable":[78],"oral":[79],"bioavailability,":[80],"excellent":[81],"brain":[82],"uptake,":[83],"robust":[85],"vivo":[87],"efficacy":[88],"validated":[91],"depression":[92],"model.":[93],"Over":[94],"course":[96],"this":[98],"work,":[99],"novel":[101],"heterocycle-directed":[102],"asymmetric":[103],"hydrogenation":[104],"was":[105],"developed":[106],"facilitate":[108],"installation":[109],"key":[112],"stereogenic":[113],"center.":[114]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-10-28T00:00:00"}